Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Incyte: Clinical Trials & FDA Approval Profile

Incyte (Wilmington, DE) sponsors 119 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 38 active protocols (16 recruiting now), 47 completed protocols, and 6 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)28.6%
Median Closed Enrollment vs National (145 pts)99 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Incyte
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)119
Active Pipeline (Recruiting Now)38 (16)
Completed vs Stopped Early47 / 34 (28.6%)
Median Closed Actual Enrollment99 participants
Physical Hospital Site Disclosure82.7% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals6 (5 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Incyte
Hospital Research SiteLocationShared Protocols
Hospital Universitario 12 de OctubreMadrid19
Hospital Universitario Ramon y CajalMadrid17
Hospital de La Santa Creu I Sant PauBarcelona17

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Incyte
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06804811A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoPhase IIIRECRUITING
NCT07023627A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPhase IIRECRUITING
NCT07623200A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaPhase IIIRECRUITING
NCT05090891To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaPhase IIRECRUITING
NCT06585774A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseasePhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Incyte Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI